E
AXIM Biotechnologies, Inc.
AXIM
$0.003
$0.000.00%
E
Sell
6/26/2024Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
E
Sell
6/7/2024Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E from E+ on 6/7/2024 due to a decline in the volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E from E+ on 6/7/2024 due to a decline in the volatility index.
E
Sell
6/4/2024Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/17/2024Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from -0.95 to -0.75.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from -0.95 to -0.75.
E
Sell
3/14/2023Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 03/14/2023.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D- from E+ on 02/23/2023.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from -1.52 to -1.29.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from -1.52 to -1.29.
D
Sell
5/5/2022Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
4/18/2022Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 4/18/2022 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0246 to -$0.0589, operating cash flow declined 48.82% from -$532.8 to -$792.9, and total revenue declined 40.74% from $8.1 to $4.8.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 4/18/2022 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0246 to -$0.0589, operating cash flow declined 48.82% from -$532.8 to -$792.9, and total revenue declined 40.74% from $8.1 to $4.8.
D
Sell
3/30/2022Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 3/30/2022 due to an increase in the valuation index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 3/30/2022 due to an increase in the valuation index.
D
Sell
3/15/2022Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 3/15/2022 due to a noticeable decline in the total return index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 3/15/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from E+ on 11/23/2021 due to a large increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.03 to -$0.0246, and operating cash flow increased 10.53% from -$595.5 to -$532.8.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from E+ on 11/23/2021 due to a large increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.03 to -$0.0246, and operating cash flow increased 10.53% from -$595.5 to -$532.8.
E
Sell
11/8/2021Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
D
Sell
10/14/2021Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 10/14/2021 due to a noticeable decline in the total return index, valuation index and solvency index. The quick ratio declined from 0.37 to 0.16, and debt to equity increased from 3.87 to 5.86.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 10/14/2021 due to a noticeable decline in the total return index, valuation index and solvency index. The quick ratio declined from 0.37 to 0.16, and debt to equity increased from 3.87 to 5.86.
D
Sell
3/15/2021Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 3/15/2021 due to an increase in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 3/15/2021 due to an increase in the total return index.
D
Sell
11/20/2020Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 11/20/2020 due to a major decline in the growth index and valuation index. Earnings per share declined from -$0.004 to -$0.0169, and EBIT declined 92.95% from -$659.7 to -$1.27M.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 11/20/2020 due to a major decline in the growth index and valuation index. Earnings per share declined from -$0.004 to -$0.0169, and EBIT declined 92.95% from -$659.7 to -$1.27M.
D
Sell
6/12/2020Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 6/12/2020 due to an increase in the volatility index, growth index and total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 6/12/2020 due to an increase in the volatility index, growth index and total return index.
D
Sell
5/15/2020Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 5/15/2020 due to a significant decline in the efficiency index, solvency index and growth index. Net income declined 66.29% from -$863.6 to -$1.44M, earnings per share declined from -$0.0138 to -$0.0226, and total capital declined 38.36% from $1.48M to $912.1.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 5/15/2020 due to a significant decline in the efficiency index, solvency index and growth index. Net income declined 66.29% from -$863.6 to -$1.44M, earnings per share declined from -$0.0138 to -$0.0226, and total capital declined 38.36% from $1.48M to $912.1.
D
Sell
11/5/2019Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 11/5/2019 due to a large decline in the total return index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 11/5/2019 due to a large decline in the total return index and volatility index.
D
Sell
10/7/2019Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D+ from C- on 10/7/2019 due to a decline in the volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D+ from C- on 10/7/2019 due to a decline in the volatility index.
C
Hold
8/19/2019Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D on 8/19/2019 due to a significant increase in the efficiency index, growth index and solvency index. Total revenue increased 444.44% from $17.1 to $93.1, earnings per share increased from -$0.0389 to -$0.0293, and net income increased 22.95% from -$2.34M to -$1.81M.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D on 8/19/2019 due to a significant increase in the efficiency index, growth index and solvency index. Total revenue increased 444.44% from $17.1 to $93.1, earnings per share increased from -$0.0389 to -$0.0293, and net income increased 22.95% from -$2.34M to -$1.81M.
D
Sell
8/16/2018Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 8/16/2018 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 0.09 to 0.07.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 8/16/2018 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 0.09 to 0.07.
D
Sell
5/30/2018Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 5/30/2018 due to a significant increase in the efficiency index, valuation index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 5/30/2018 due to a significant increase in the efficiency index, valuation index and volatility index.
D
Sell
1/26/2018Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 1/26/2018 due to a decline in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 1/26/2018 due to a decline in the total return index.
D
Sell
1/9/2018Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 1/9/2018 due to an increase in the total return index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 1/9/2018 due to an increase in the total return index and volatility index.
D
Sell
11/21/2017Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 11/21/2017 due to an increase in the efficiency index, total return index and solvency index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 11/21/2017 due to an increase in the efficiency index, total return index and solvency index.
D
Sell
8/22/2017Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 8/22/2017 due to a major decline in the growth index and total return index. Total revenue declined 80.11% from $18.6 to $3.7, and earnings per share declined from -$0.01 to -$0.0107.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 8/22/2017 due to a major decline in the growth index and total return index. Total revenue declined 80.11% from $18.6 to $3.7, and earnings per share declined from -$0.01 to -$0.0107.
D
Sell
5/23/2017Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 5/23/2017 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0274 to -$0.01, total revenue increased 52.46% from $12.2 to $18.6, and EBIT increased 38.16% from -$770.2 to -$476.3.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 5/23/2017 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0274 to -$0.01, total revenue increased 52.46% from $12.2 to $18.6, and EBIT increased 38.16% from -$770.2 to -$476.3.
D
Sell
4/28/2017Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from C- on 4/28/2017 due to a noticeable decline in the efficiency index, total return index and valuation index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from C- on 4/28/2017 due to a noticeable decline in the efficiency index, total return index and valuation index.
C
Hold
3/22/2017Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D+ on 3/22/2017 due to a noticeable increase in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D+ on 3/22/2017 due to a noticeable increase in the total return index.
D
Sell
3/3/2017Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D+ from C- on 3/3/2017 due to a decline in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D+ from C- on 3/3/2017 due to a decline in the total return index.
C
Hold
1/30/2017Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D+ on 1/30/2017 due to a substantial increase in the total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to C- from D+ on 1/30/2017 due to a substantial increase in the total return index.
D
Sell
11/22/2016Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 11/22/2016 due to a substantial increase in the total return index, efficiency index and growth index. Earnings per share increased from -$0.0475 to -$0.007, operating cash flow increased 38.68% from -$352.4 to -$216.1, and net income increased 5.56% from -$1.89M to -$1.78M.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 11/22/2016 due to a substantial increase in the total return index, efficiency index and growth index. Earnings per share increased from -$0.0475 to -$0.007, operating cash flow increased 38.68% from -$352.4 to -$216.1, and net income increased 5.56% from -$1.89M to -$1.78M.
D
Sell
9/7/2016Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 9/7/2016 due to a significant decline in the efficiency index, total return index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 9/7/2016 due to a significant decline in the efficiency index, total return index and volatility index.
D
Sell
8/23/2016Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 8/23/2016 due to a significant increase in the efficiency index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D on 8/23/2016 due to a significant increase in the efficiency index and volatility index.
D
Sell
5/31/2016Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 5/31/2016 due to a significant decline in the efficiency index, solvency index and volatility index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D from D+ on 5/31/2016 due to a significant decline in the efficiency index, solvency index and volatility index.
D
Sell
4/15/2016Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D- on 4/15/2016 due to a significant increase in the efficiency index, valuation index and total return index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D+ from D- on 4/15/2016 due to a significant increase in the efficiency index, valuation index and total return index.
D
Sell
3/11/2016Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index.
D
Sell
10/26/2015Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 10/26/2015 due to an increase in the valuation index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 10/26/2015 due to an increase in the valuation index.
D
Sell
8/21/2015Downgrade
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 8/21/2015 due to a large decline in the solvency index, total return index and valuation index. The quick ratio declined from 0.15 to 0.02.
AXIM Biotechnologies, Inc. (AXIM) was downgraded to D- from D on 8/21/2015 due to a large decline in the solvency index, total return index and valuation index. The quick ratio declined from 0.15 to 0.02.
D
Sell
11/3/2014Upgraded
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 11/3/2014 due to an increase in the volatility index.
AXIM Biotechnologies, Inc. (AXIM) was upgraded to D from D- on 11/3/2014 due to an increase in the volatility index.
D
Sell
7/1/2014Upgraded
Axim International Inc. (AXIM) was upgraded to D- from E+ on 7/1/2014 due to a large increase in the solvency index, total return index and growth index.
Axim International Inc. (AXIM) was upgraded to D- from E+ on 7/1/2014 due to a large increase in the solvency index, total return index and growth index.
E
Sell
4/1/2014Upgraded
Axim International Inc. (AXIM) was upgraded to E+ from E on 4/1/2014 due to a noticeable increase in the total return index and volatility index.
Axim International Inc. (AXIM) was upgraded to E+ from E on 4/1/2014 due to a noticeable increase in the total return index and volatility index.
E
Sell
3/28/2014None
OTC PK
03/06/2025 1:07PM Eastern
Quotes delayed
